HUDSON, N.Y., Aug 15 (Bernama-GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement with Cergentis B.V. ("Cergentis") to leverage the company's Targeted Locus Amplification (TLA) technology to provide transgene mapping services to its customers.
While transgenic mice generated via random pro-nuclear injection (PNI) continue to be a critical tool in biomedical research, a distinct disadvantage of these models is the inability to direct the transgene to a specific integration site within the genome. Cergentis has developed a next generation sequencing method based on their patented TLA technology. Taconic's Transgene Mapping Analysis (TgMA) service leverages this platform, making the task of determining the precise location of a randomly inserted transgene much easier. In addition to the sequencing data from Cergentis, Taconic provides expert interpretation specific to the transgenic line, leading to an optimized breeding strategy.
While transgenic mice generated via random pro-nuclear injection (PNI) continue to be a critical tool in biomedical research, a distinct disadvantage of these models is the inability to direct the transgene to a specific integration site within the genome. Cergentis has developed a next generation sequencing method based on their patented TLA technology. Taconic's Transgene Mapping Analysis (TgMA) service leverages this platform, making the task of determining the precise location of a randomly inserted transgene much easier. In addition to the sequencing data from Cergentis, Taconic provides expert interpretation specific to the transgenic line, leading to an optimized breeding strategy.
No comments:
Post a Comment